Clinical trials: Oral Malignancy
Advanced Cancer
A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)
This study will evaluate the safety and tolerability of continuing vorinostat (MK-0683) dosing in cancer patients previously enrolled in one of five base studies (MK-0683-001, MK-0683-006, MK-0683-008, MK-0683-012, or…
- Trial name
- NCT00907738
- Testing
- vorinostat
- Volunteers
- 27 people
- Sponsor
- Merck Sharp & Dohme LLC
Dysphagia, Oral Pharyngeal Cancer
Pilot Study to Improve Therapeutic Outcomes for Dysphagia After Radiation Therapy
Patients with head and neck cancer treated with chemoradiation, often develop a treatment associated dysphagia. The common complaint is foods sticking in the pharynx.
- Trial name
- NCT02564887
- Testing
- Iowa Oral Performance Instrument
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Jonas Johnson
Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic
A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma
This is a Phase 1 dose-exploration study of LAM-002A administered by mouth in patients with relapsed or refractory B-cell NHL. Safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD),and preliminary anti-tumor activity…
- Trial name
- LAM-002A/NHL (NCT02594384)
- Testing
- LAM-002A, Rituximab, Atezolizumab
- Where
- 11 sites in United States
- Volunteers
- 62 people
- Sponsor
- IRulya Therapeutics Inc.
Uterine Fibroids
A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids
The purpose of this study is to evaluate the efficacy and safety of Relugolix (TAK-385) in patients having pain symptoms associated with uterine fibroids.
- Trial name
- NCT02655224
- Testing
- Relugolix
- Where
- 11 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Takeda
Breast Cancer
Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer
This is a pilot "window of opportunity" clinical study in patients with operable breast cancer investigating use of reparixin as single agent in the time period between clinical diagnosis and surgery.
- Trial name
- NCT01861054
- Testing
- Reparixin
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dompé Farmaceutici S.p.A
Bladder Cancer, Cervical Cancer
Acceptability of Less Harmful Alternatives to Cigarettes
RATIONALE: A study that evaluates participants' beliefs about smokeless tobacco products and nicotine replacement therapy may be useful in helping smokers stop smoking.
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00957424
- Testing
- telephone-based intervention, nicotine replacement therapy, informational intervention
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Roswell Park Cancer Institute
Carcinoma, Non-Small-Cell Lung, Lung Cancer
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
Background: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Lung cancer is the leading cause of cancer-related death in the United States.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Esophageal
- Trial name
- NCT03233724
- Testing
- Decitabine (DAC), Tetrahydrouridine (THU), Pembrolizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Neoplasms
Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma
Since the mortality rates for patients with advanced ovarian carinoma are high, the most likely way to improve progression free and overall survival is with maximal "upfront" therapy (Morrow \& Curtin, 1998).
- Trial name
- NCT00976183
- Testing
- Vorinostat
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Gynecologic Oncology Associates
Ulcerative Colitis
Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy
Evaluation of the intraepithelial neoplasia detection rate in patients with long standing ulcerative colitis undergoing mucosal staining with oral methylene blue MMX tablets prior to colonoscopy.
- Trial name
- NCT01520324
- Testing
- oral delivery mucosal stain
- Where
- Italy
- Volunteers
- 53 people
- Sponsor
- Cosmo Technologies Ltd
Erythroplakia, Oral Leukoplakia
Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia
This phase IIb trial tests whether metformin works in preventing oral cancer in patients with oral leukoplakia (white patches) or erythroplakia (red patches). Metformin is in a class of drugs called biguanides.
- Trial name
- NCT05237960
- Testing
- Biopsy, Biospecimen Collection, Extended Release Metformin Hydrochloride
- Where
- 10 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- University of Arizona
Prostate Cancer, Castration-resistant Prostate Cancer
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
Previous studies of high dose testosterone therapy given intramuscularly to men with metastatic castrate resistant prostate cancer suggest that high serum levels of testosterone may be required for clinical response.
- Conditions
- Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Trial name
- NCT05081193
- Testing
- Testosterone Undecanoate, Enzalutamide
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adenocarcinoma, Pancreatic Neoplasms
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
This study is to evaluate the combination of an investigational drug X-82 with everolimus in the treatment of pancreatic neuroendocrine tumors.
- Trial name
- NCT01784861
- Testing
- X-82, Everolimus
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Washington University School of Medicine
Pancreatic Neoplasms, Bile Duct Neoplasms
CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma
This study involves the use of oxaliplatin, capecitabine, and sorafenib which are all drugs approved by the Food and Drug Administration (FDA) for use in the treatment of different cancers.
- Trial name
- NCT00634751
- Testing
- Oxaliplatin, Capecitabine, Sorafenib
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Wisconsin, Madison
Multiple Myeloma
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
The purpose of this study was to determine clinical efficacy and safety of ruxolitinib (INCB018424), a small molecule Janus kinase 2 (JAK2)-inhibitor, in patients with refractory or relapsed multiple myeloma.
- Trial name
- NCT00639002
- Testing
- Ruxolitinib 25 mg, Dexamethasone 40 mg
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Incyte Corporation
Psoriasis
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01309737
- Testing
- CP-690,550
- Where
- 94 sites in United States, Canada and 9 more
- Volunteers
- 960 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Study to evaluate the efficacy and safety of capmatinib as a single-agent treatment for subjects with advanced/metastatic (stage IIIB or IV) non-small cell lung cancer (NSCLC) who had wild-type epidermal growth factor receptor…
- Trial name
- NCT02414139
- Testing
- Capmatinib
- Where
- 95 sites in United States, Argentina and 18 more
- Volunteers
- 373 people
- Sponsor
- Novartis Pharmaceuticals
Salivary Gland Cancer
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
The purpose of this study is to find out what effects, good and/or bad, treatment with two drugs called nivolumab and ipilimumab have on the participant and salivary cancer.
- Trial name
- NCT03172624
- Testing
- Nivolumab, Ipilimumab
- Where
- 8 sites in United States
- Volunteers
- 64 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Polycystic Ovary Syndrome (PCOS), Overweight
The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS
Polycystic ovary syndrome (PCOS) is a health problem that affects one in 10 women of childbearing age, which is usually characterized by hormonal imbalance and metabolism problems such as hyperandrogenism and obesity.
- Conditions
- Polycystic Ovary Syndrome (PCOS), Overweight, Obesity
- Trial name
- NCT03151005
- Testing
- Metformin-GLP-1 Receptor Agonist, Metformin-Oral Contraceptive(OC)
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Xinqiao Hospital of Chongqing
Neoplasms
A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel
To establish the maximum tolerated dose (MTD) of oral afatinib (BIBW2992) given in combination with gemcitabine or docetaxel in patients with relapsed or refractory tumors. To assess the safety of the combination.
- Trial name
- NCT01251653
- Testing
- Afatinib, docetaxel, gemcitabine
- Where
- 3 sites in France
- Volunteers
- 94 people
- Sponsor
- Boehringer Ingelheim
Mouth Neoplasms, Head and Neck Neoplasms
Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma
Background: Advanced-stage head and neck cancer (head and neck squamous cell carcinoma [HNSCC]) has moderately successful treatment outcomes, usually involving surgery as part of the standard treatment.
- Conditions
- Mouth Neoplasms, Head and Neck Neoplasms, Tongue Neoplasms, Carcinoma, Squamous Cell
- Trial name
- NCT01195922
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)